

# Hasan Yazici

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/687087/publications.pdf>

Version: 2024-02-01

65  
papers

2,447  
citations

394286

19  
h-index

197736

49  
g-index

68  
all docs

68  
docs citations

68  
times ranked

2174  
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213225.	0.5	442
2	A double-blind trial of colchicine in Behçet's syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 2686-2692.	6.7	358
3	Behçet syndrome: a contemporary view. <i>Nature Reviews Rheumatology</i> , 2018, 14, 107-119.	3.5	281
4	Behçet's disease: diagnostic and prognostic aspects of neurological involvement. <i>Journal of Neurology</i> , 2001, 248, 95-103.	1.8	276
5	Behçet's syndrome: disease manifestations, management, and advances in treatment. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 148-155.	3.2	247
6	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , 2018, 57, 2200-2212.	0.9	89
7	The Place of Behçet's Syndrome Among the Autoimmune Diseases. <i>International Reviews of Immunology</i> , 1997, 14, 1-10.	1.5	72
8	Pulmonary artery involvement in Behçet's syndrome: Effects of anti-Tnf treatment. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 369-373.	1.6	64
9	An outcome survey of 43 patients with Budd-Chiari syndrome due to Behçet's syndrome followed up at a single, dedicated center. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 602-609.	1.6	59
10	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 752-762.	1.6	56
11	Criteria for Behçet's disease with reflections on all disease criteria. <i>Journal of Autoimmunity</i> , 2014, 48-49, 104-107.	3.0	50
12	Behçet's syndrome: An update. <i>Current Rheumatology Reports</i> , 2003, 5, 195-199.	2.1	47
13	Behçet Syndrome Manifestations and Activity in the United States versus Turkey – A Cross-sectional Cohort Comparison. <i>Journal of Rheumatology</i> , 2014, 41, 1379-1384.	1.0	42
14	ACUTE FEBRILE NEUTROPHILIC DERMATOSIS (SWEET'S SYNDROME) ASSOCIATED WITH BEHÇET'S DISEASE. <i>International Journal of Dermatology</i> , 1992, 31, 645-646.	0.5	34
15	EPIDEMIOLOGY OF BEHÇET'S SYNDROME IN TURKEY. <i>International Journal of Dermatology</i> , 1996, 35, 618-620.	0.5	34
16	A familial syndrome of pericarditis, arthritis, camptodactyly, and coxa vara. <i>Arthritis and Rheumatism</i> , 1986, 29, 436-438.	6.7	32
17	Takayasu disease with prominent pulmonary artery involvement: confusion with pulmonary disease leading to delayed diagnosis. <i>Modern Rheumatology</i> , 2008, 18, 507-510.	0.9	22
18	Amyloidosis in behçet's syndrome. <i>Arthritis and Rheumatism</i> , 1990, 33, 1586-1589.	6.7	21

#	ARTICLE	IF	CITATIONS
19	Wound healing in Behçet's syndrome. International Journal of Dermatology, 1998, 37, 120-123.	0.5	21
20	Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. Journal of Rheumatology, 2015, 42, 2436-2441.	1.0	18
21	Diagnostic versus classification criteria - a continuum. Bulletin of the NYU Hospital for Joint Diseases, 2009, 67, 206-8.	0.7	16
22	The HLA Association of Lepromatous Leprosy and Borderline Lepromatous Leprosy in Turkey.. International Journal of Dermatology, 1988, 27, 246-247.	0.5	13
23	Behçet's Syndrome. BioDrugs, 1995, 3, 102-107.	0.7	13
24	Assessment of deep venous thrombosis in the lower extremity in Behçet's syndrome: MR venography versus Doppler ultrasonography. Internal and Emergency Medicine, 2019, 14, 705-711.	1.0	13
25	Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behçet's syndrome patients with pulmonary artery involvement during follow-up. Clinical and Experimental Rheumatology, 2016, 34, 92-96.	0.4	13
26	The prevalence of Behçet's disease in the north of Jordan: a hospital-based epidemiological survey. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 51-54.	0.4	10
27	Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 86-89.	0.4	9
28	Fatigue is correlated with disease activity but not with the type of organ involvement in Behçet's syndrome: a comparative clinical survey. Clinical and Experimental Rheumatology, 2015, 33, S107-12.	0.4	8
29	To anticoagulate or not to anticoagulate vascular thrombosis in Behçet's syndrome: an enduring question. Clinical and Experimental Rheumatology, 2016, 34, S3-4.	0.4	8
30	Venous claudication in Behçet's disease. Journal of Vascular Surgery, 2015, 62, 698-703.e1.	0.6	7
31	Diagnosis and/or classification of vasculitis. Current Opinion in Rheumatology, 2016, 28, 3-7.	2.0	7
32	Beware of registries for their biases. Bulletin of the NYU Hospital for Joint Diseases, 2012, 70, 95-8.	0.7	7
33	Behçet's syndrome in the 2000s: "Where is the wisdom we have lost in knowledge?". Clinical and Experimental Rheumatology, 2016, 34, 23-25.	0.4	7
34	Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 95-99.	0.4	6
35	A critical look at diagnostic criteria: time for a change?. Bulletin of the NYU Hospital for Joint Diseases, 2011, 69, 101-3.	0.7	5
36	There was less self-critique among basic than in clinical science articles in three rheumatology journals. Journal of Clinical Epidemiology, 2014, 67, 654-657.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Self-criticism in Behçet's disease and other autoinflammatory conditions. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S5-6.	0.4	4
38	Histopathological and clinical evaluation of papulopustular lesions in Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S101-6.	0.4	4
39	Behçet's disease: an MHC-I-opathy?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 104, 5.	0.4	4
40	An update on vasculitides – lumps and constructs. <i>Current Opinion in Rheumatology</i> , 2017, 29, 1-3.	2.0	3
41	Pulmonary artery aneurysms in Behçet's syndrome: a review of the literature with emphasis on geographical differences. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S54-9.	0.4	3
42	A methodologic problem and a conceptual issue related to the new 2022 antineutrophil cytoplasmic antibody-related vasculitis criteria sets: comment on criteria sets approved by the American College of Rheumatology Board of Directors and the European Alliance of Associations for Rheumatology Executive Committee. <i>Arthritis and Rheumatology</i> , 2022, 74, 1724-1725.	2.9	3
43	Vasculitis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 1-2.	2.0	2
44	A double-blind trial of colchicine in Behçet's syndrome. , 2001, 44, 2686.		2
45	Familial Mediterranean fever: different faces around the world. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 121, 18-22.	0.4	2
46	Editorial: Introduction, vasculitis 2020. <i>Current Opinion in Rheumatology</i> , 2020, 32, 1-2.	2.0	1
47	Disease Classification/Diagnosis Criteria. , 2014, , 65-78.		1
48	The P-value crisis and the issue of causality. <i>Rheumatology</i> , 2020, 59, 1467-1468.	0.9	1
49	Alcohol and Ventricular Arrhythmia. <i>Annals of Internal Medicine</i> , 1973, 78, 153.	2.0	1
50	Behçet Syndrome as a Construct. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1585-1586.	0.4	1
51	Use and abuse of the controlled clinical trial. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2007, 65, 132-4.	0.7	1
52	Thought barriers to understanding rheumatic diseases–Halstead R. Holman revisited. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2010, 68, 143-6.	0.7	1
53	Effect of colchicine on serum lipid levels. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S136.	0.4	1
54	Ethical Issues in Study Design and Reporting. , 2014, , 247-263.		0

#	ARTICLE	IF	CITATIONS
55	Response to the letter by Andrea Mancuso. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, e2.	1.6	0
56	Inadequate reporting of enrolled patient and study site characteristics, and inter-study site differences in randomized controlled trials: A systematic review in six leading medicine journals. <i>European Journal of Internal Medicine</i> , 2017, 37, e34-e36.	1.0	0
57	240.â€fFACTORS ASSOCIATED WITH DAMAGE PROGRESSION IN BEHÇETâ€™S SYNDROME UVEITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
58	Correspondence on â€classification criteria: time for a rethink â€by D Porter<i>et alâ€™</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e176-e176.	0.5	0
59	The winter of my discontent. <i>Turkish Archives of Pediatrics</i> , 2021, 56, 177-178.	0.5	0
60	Concerns Regarding the Analysis of a Takayasu Arteritis Cohort: Comment on the Article by Goel et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 1948-1948.	2.9	0
61	A Few Suggestions for Further Research. , 2020, , 315-319.		0
62	What is wrong with what is said?. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2008, 66, 140-2.	0.7	0
63	The post modern p=1.0. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S8.	0.4	0
64	Acknowledged statistical help and a better use of p values: a proposal. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 855-857.	0.4	0
65	The Editor's note. First taking the log out of our own eyes. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 128, 1.	0.4	0